24/7 Market News Snapshot 16 September, 2025 – Harvard Bioscience Inc (NASDAQ:HBIO)
DENVER, Colo., 16 September, 2025 (www.247marketnews.com) – (NASDAQ:HBIO) are discussed in this article.
Harvard Bioscience, Inc. is experiencing a notable upswing in its stock performance, evident in pre-market trading where shares surged by 8.99%, reaching $0.479 from the previous close of $0.440. The trading volume has significantly increased to 5.15 million shares, indicating heightened investor interest and strong market momentum. This upward trend may suggest positive market sentiment, potentially fueled by anticipated product announcements or forthcoming financial results. Market analysts advise monitoring key resistance levels around $0.50 while identifying support at the previous close. Should this upward pressure persist, further gains could materialize, although cautious trading is recommended if volume declines.
In tandem with its financial performance, Harvard Bioscience has announced a strategic expansion of its distribution agreement with Fisher Scientific, a leading global supplier of scientific products. This broadened collaboration will allow Fisher Scientific to market a wider selection of Harvard Bioscience’s innovative laboratory equipment, including pumps and BTX electroporation systems across North America. The enhanced partnership builds on a successful agreement in Europe and provides Harvard Bioscience with access to Fisher Scientific’s extensive sales network, which is expected to enhance customer reach and introduce advanced technologies such as the Mesh MEA (Microelectrode Array) for organoid research.
According to John Duke, President and CEO of Harvard Bioscience, this expansion is crucial in enhancing product accessibility and improving the overall customer experience through streamlined ordering and faster delivery. By maximizing convenience, the company is set to strengthen its position as a leader in laboratory instruments and technologies, supporting vital advancements in life sciences, drug discovery, and preclinical testing. This initiative underscores Harvard Bioscience’s commitment to facilitating scientific discovery and providing the tools necessary for researchers to excel in their work.